THERATECHNOLOGIES INC (THTX) Stock Overview
NASDAQ:THTX - CA88338H7040 - Common Stock
THTX Key Statistics, Chart & Performance
The current stock price of THTX is 3.28 USD. In the past month the price increased by 2.66%. In the past year, price increased by 142.96%.
THTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.7 | 368.47B | ||
| AMGN | AMGEN INC | 12.81 | 150.41B | ||
| GILD | GILEAD SCIENCES INC | 14.91 | 143.15B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.21 | 100.83B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.16 | 58.81B | ||
| ARGX | ARGENX SE - ADR | 81.97 | 46.50B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.02 | 40.92B | ||
| INSM | INSMED INC | N/A | 30.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.89B | ||
| NTRA | NATERA INC | N/A | 22.95B | ||
| BIIB | BIOGEN INC | 8.87 | 20.81B |
Related stock screener links
About THTX
Company Profile
Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The company is headquartered in Montreal, Quebec and currently employs 94 full-time employees. The firm offers prescription products for individuals with human immunodeficient virus (HIV) in the United States and its pipeline is focused on specialized therapies designed to address unmet medical needs in both HIV and oncology. The company markets two HIV products, namely EGRIFTA SV and Trogarzo; and has research programs in HIV and oncology. EGRIFTA SV is the therapy for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Trogarzo injection is used with other antiretrovirals to treat HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 who are failing their current regimen. Its pipeline includes Donidalorsen and Olezarsen, and the SORT1+ oncology platform. The firm is also focusing on tesamorelin life-cycle management in lipodystrophy.
Company Info
THERATECHNOLOGIES INC
2015 Peel Street, 11th Floor
MONTREAL QUEBEC H3A 1T8 CA
CEO: Paul Levesque
Employees: 103
Phone: 15143367800
THERATECHNOLOGIES INC / THTX FAQ
What is the stock price of THERATECHNOLOGIES INC today?
The current stock price of THTX is 3.28 USD. The price increased by 0.31% in the last trading session.
What is the ticker symbol for THERATECHNOLOGIES INC stock?
The exchange symbol of THERATECHNOLOGIES INC is THTX and it is listed on the Nasdaq exchange.
On which exchange is THTX stock listed?
THTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for THERATECHNOLOGIES INC stock?
10 analysts have analysed THTX and the average price target is 4.06 USD. This implies a price increase of 23.9% is expected in the next year compared to the current price of 3.28. Check the THERATECHNOLOGIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is THERATECHNOLOGIES INC worth?
THERATECHNOLOGIES INC (THTX) has a market capitalization of 150.81M USD. This makes THTX a Micro Cap stock.
How many employees does THERATECHNOLOGIES INC have?
THERATECHNOLOGIES INC (THTX) currently has 103 employees.
What are the support and resistance levels for THERATECHNOLOGIES INC (THTX) stock?
THERATECHNOLOGIES INC (THTX) has a support level at 3.25 and a resistance level at 3.29. Check the full technical report for a detailed analysis of THTX support and resistance levels.
Is THERATECHNOLOGIES INC (THTX) expected to grow?
The Revenue of THERATECHNOLOGIES INC (THTX) is expected to decline by -3.03% in the next year. Check the estimates tab for more information on the THTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy THERATECHNOLOGIES INC (THTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of THTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of THTX, evaluating the profitability, health, valuation and growth aspects
- THERATECHNOLOGIES INC (THTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- THERATECHNOLOGIES INC (THTX) Sales and EPS estimates to see what analysts future expectations are.
- THERATECHNOLOGIES INC (THTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- THERATECHNOLOGIES INC (THTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- THERATECHNOLOGIES INC (THTX) Stock Chart to make your own analysis
- THERATECHNOLOGIES INC (THTX) Latest news and press-releases to stay up to date.
Does THERATECHNOLOGIES INC (THTX) stock pay dividends?
THTX does not pay a dividend.
When does THERATECHNOLOGIES INC (THTX) report earnings?
THERATECHNOLOGIES INC (THTX) will report earnings on 2025-10-08, before the market open.
What is the Price/Earnings (PE) ratio of THERATECHNOLOGIES INC (THTX)?
THERATECHNOLOGIES INC (THTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.19).
What is the Short Interest ratio of THERATECHNOLOGIES INC (THTX) stock?
The outstanding short interest for THERATECHNOLOGIES INC (THTX) is 0.86% of its float. Check the ownership tab for more information on the THTX short interest.
THTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to THTX. When comparing the yearly performance of all stocks, THTX is one of the better performing stocks in the market, outperforming 96.15% of all stocks.
THTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to THTX. While THTX is still in line with the averages on profitability rating, there are concerns on its financial health.
THTX Financial Highlights
Over the last trailing twelve months THTX reported a non-GAAP Earnings per Share(EPS) of -0.19.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.86% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
THTX Forecast & Estimates
10 analysts have analysed THTX and the average price target is 4.06 USD. This implies a price increase of 23.9% is expected in the next year compared to the current price of 3.28.
For the next year, analysts expect an EPS growth of 88.56% and a revenue growth -3.03% for THTX